Trial · NCT07886476
IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
NCT07886476, Phase 1, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy. Trials, record NCT07886476. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886476
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
- NCT number
- NCT07886476
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Conditions
- IgA Nephropathy (IgAN)
- Interventions
- IBI3034, Placebo, Telitacicept
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety: Incidence of adverse events (AEs) and serious adverse events (SAEs) following a single dose of IBI3034 in healthy participants(Part 1) | through study completion,an average of 169 days | |
| Primary | Safety: Incidence of AEs and SAEs following multiple doses of IBI3034 in participants with primary IgA nephropathy(Part 2) | through study completion,an average of 252 days | |
| Secondary | Pharmacodynamic (PD) Profile: Change from baseline in serum immunoglobulin levels(Part 1) | through study completion,an average of 169 days | |
| Secondary | Exploratory Clinical Profile: Change from baseline in UPCR(Part2) | through study completion,an average of 252 days | |
| Secondary | Pharmacodynamic (PD) Profile: Change from baseline in serum immunoglobulin levels (Part 2) | through study completion,an average of 252 days | |
| Secondary | Exploratory Clinical Profile: Change from baseline in UACR (Part 2) | through study completion,an average of 252 days | |
| Secondary | Exploratory Clinical Profile: Change from baseline in eGFR (Part 2) | through study completion,an average of 252 days | |
| Secondary | Exploratory Clinical Profile: Change from baseline in hematuria(Part2) | through study completion,an average of 252 days | |
| Secondary | Exploratory Clinical Profile: Change from baseline in serum albumin(Part2) | through study completion,an average of 252 days | |
| Secondary | Exploratory Clinical Profile: Change from baseline in serum creatinine(Part2) | through study completion,an average of 252 days |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886476
GET https://conductscience.org/api/trials/v1/NCT07886476/registered?page=2